New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
16:46 EDTIMUCImmunoCellular presents updated ICT-107 Phase II data
ImmunoCellular Therapeutics announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme, GBM, were presented at the 2014 American Society for Clinical Oncology, ASCO, annual meeting in Chicago. When overall survival. OS, and progression-free survival, PFS, were assessed in pre-specified patient subgroups, results favored treatment with ICT-107 over control in HLA-A2 patients within each of the two major MGMT subgroups. While the subgroups were small in size, and not powered to show statistical significance, the numeric advantages in favor of ICT-107 treated patients were shown to be large and clinically meaningful. HLA, human leukocyte antigens, are cell-surface antigen-presenting proteins. These molecules are on dendritic cells and present the tumor-associated antigens to T-cells to induce the immune response to the ICT-107 vaccine. HLA-A2 was one of two HLA types that were treated in the phase II trial. Of the two types, HLA-A2 is twice as common in the population as HLA-A1, and is the most common HLA type in North America and the EU.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
09:15 EDTIMUCImmunoCellular to host conference call
President & CEO Gengos discusses the ICT-107 updated data presented at the recently-held Society for Neuro-Oncology's 19th Annual Scientific Meeting on a conference call to be held on November 18 at 5 pm. Webcast Link
November 14, 2014
06:10 EDTIMUCImmunoCellular jpresents positive Phase II data for ICT-107
ImmunoCellular announces the presentation of updated efficacy data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107. Consistent with prior data presentations in December 2013 and June 2014, the results demonstrate a statistically significant progression-free survival benefit, and a numeric overall survival benefit in ICT-107 treated patients compared to the control group. The ICT-107 treatment effect continues to be strongest in the pre-defined HLA-A2 subgroup of patients in which the MGMT methylated patients showed the largest treatment effect, with a significant PFS advantage over the control group, and continued potential for the OS advantage to move toward significance as more events occur. There were no differences in adverse events between the ICT-107 treated group and the control group. The company is utilizing all available information from the controlled phase II trial to design phase III testing in order to increase its probability of success, including the timing of randomization within the standard-of-care treatment these patients receive, in an attempt to limit the number of patients who are "early progressors" and unlikely to respond to therapy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use